文献速递慢阻肺呼吸危重症与机械通气

经鼻高流量氧疗与无创通气在慢阻肺慢性呼吸衰竭患者中的随机交叉对照试验

Nasal high-flow therapy compared with non-invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross-over trial.
PubMed 文献 · Respirology · 2019-05-13

主要终点为60分钟时经皮二氧化碳分压(PtCO2),NIV降低PtCO2幅度大于NHF(-5.3 vs -2.5 mm Hg,差值-2.8 mm Hg,P=0.021),但NHF在应用便利性、舒适度和贴合度方面评分更优。

要点

  • NIV降低PtCO2优于NHF,但临床意义不确定。
  • NHF耐受性更好,可作为部分高碳酸血症呼吸衰竭患者的选择。
  • 两种方式在PtCO2下降≥4或≥8 mm Hg的比例上无显著差异。

核心结论

  • 在稳定期高碳酸血症慢阻肺患者中,NIV降低PtCO2的幅度大于NHF,但临床意义不确定。
  • NHF耐受性优于NIV,可能作为部分高碳酸血症呼吸衰竭患者的治疗选择。

研究设计与样本

  • 单盲随机对照两阶段交叉单中心试验,在新西兰开展。

主要发现

  • 60分钟时NIV降低PtCO2幅度大于NHF(均值(SD):-5.3(5.0)vs -2.5(3.5)mm Hg;差值:-2.8(-5.0至-0.5),P=0.021)。
  • 所有时间点差值:-2.5 mm Hg(95%CI -4.5至-0.5,P=0.016)。
  • PtCO2下降≥4或≥8 mm Hg的参与者比例无显著差异。
  • 参与者对NHF在应用便利性、舒适度和贴合度方面的评分显著更好。

临床怎么用

  • 对于需要降低CO2的稳定期高碳酸血症慢阻肺患者,NIV仍为更有效的选择。
  • NHF可作为因耐受性差无法使用NIV患者的一种治疗选择。

局限性

  • 单盲设计,可能存在实施偏倚。
  • 仅评估短期(60分钟)效果,长期临床意义未明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Non-invasive ventilation (NIV) is part of the standard of care for hypercapnic respiratory failure secondary to COPD, but may be poorly tolerated. Preliminary evidence suggests nasal high-flow (NHF) therapy may improve hypercapnia in COPD and be well tolerated. We compared NHF and NIV in people with COPD and chronic hypercapnic respiratory failure. METHODS: Single-blind randomized controlled two-way cross-over single-centre trial was conducted in New Zealand. Twenty-four participants with stable hypercapnic COPD received: NHF at 45 L/min and NIV at 15/4 cm H2 O, each for 60 min with a 15-min washout in between. The primary outcome was transcutaneous partial pressure of carbon dioxide (PtCO2 ) at 60 min, adjusted for baseline. RESULTS: NIV reduced the PtCO2 more than NHF (mean (SD) at 60 min by -5.3 (5.0) vs -2.5 (3.5) mm Hg; difference: -2.8 (-5.0 to -0.5) P = 0.021). Difference across all time points was -2.5 mm Hg (95% CI -4.5 to -0.5, P = 0.016). There was no significant difference in the proportion of participants with a reduction of PtCO2 ≥ 4 or ≥ 8 mm Hg. Participants rated NHF significantly better for ease of application, comfort and fit. CONCLUSION: In stable COPD patients with chronic hypercapnia, NIV resulted in a greater reduction in PtCO2 compared with NHF, which was of uncertain clinical significance. NHF was better tolerated than NIV and may be a therapeutic option for some people with hypercapnic respiratory failure. CLINICAL TRIAL REGISTRATION: ACTRN12616001701415 at www.anzctr.org.au.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. McKinstry S, Singer J, Baarsma JP, et al. Nasal high-flow therapy compared with non-invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross-over trial. Respirology. 2019. PMID: 31083777. doi:10.1111/resp.13575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。